



NEONATAL MEDICATION PROTOCOLS

LIGNOCAINE
 Created by: NCCU
 Date for review: Sep 2016

NCCU Clinical Guidelines
 KEMH/PMH
 Perth, Western Australia

DRUG:	LIGNOCAINE
PRESENTATION:	Ampoule: 50mg in 5mL (1%)
ACTION & INDICATION:	Type 1b anti-arrhythmic agent used for control of ventricular arrhythmias
DOSE:	Loading dose: 0.5 - 1mg/kg. Repeat every 10 minutes to control arrhythmia. Maximum total bolus dose should not exceed 5mg/kg Maintenance dose: 10-50 microgram/kg/minute
PREPARATION:	Dilution for Infusion: Withdraw 30mg/kg from each ampoule and dilute it to 50mL with glucose 5%. Infuse at 1mL/hour = 10 microgram/kg/minute
ADMINISTRATION:	Intravenous: Over 5 minutes Intravenous infusion
ADVERSE EFFECTS:	CNS toxicity: drowsiness, agitation, vomiting, muscle twitching. Seizures, loss of consciousness, respiratory depression Cardiac toxicity - bradycardia, hypotension, heart block, cardiovascular collapse
COMMENTS:	Continuous monitoring of heart rate, blood pressure and ECG
REFERENCES:	Neofax 2013
DATE:	September 2013